152 BASICS
Doxycycline and minocycline: 5 mg/kg BID; GI upset; new data on breakpoints for
MIC reported.
Clindamcyin: limited use; resistance often noted with MRSP despite test results.
Fluoroquinolones: limited use due to emerging resistance.
Rifampin: hepatotoxic, potent inducer of cytochrome p450 hepatic enzymes.
Vancomycin: sensitive to the vast majority of MRS spp.; nephrotoxic in dogs.
Linezolid: excellent activity, oral or parenteral, low toxicity, very expensive; veterinary
use controversial due to its being the only effective drug in “life-threatening” human
cases.Veterinarians and physicians must commit to Antibiotic Stewardship and participate in
the One Health Initiative.
The emergence of bacterial resistance is a serious therapeutic challenge.
Fig. 7.1.Epidermal collarettes from MRSP on the ventrum of a 9-year-old female-spayed golden retriever.
These lesions cannot be distinguished from those of MSSP without culture and sensitivity testing.